Professor Wolfgang Parak is the Professor of Experimental Physics at the Philipps-University of Marburg, Germany and head of the Biofunctional Nanomaterials Unit at CIC biomaGUNE, San Sebastian, Spain, He has significantly contributed to the development of new surface chemistries of inorganic nanoparticles and towards the characterization of their physicochemical properties. In particular, the development of an amphiphilic polymer coating is nowadays used by many different groups worldwide.
During his visit to Australia, Professor Parak visited labs and gave talks:
Professor Vince Rotello is the Charles A. Goessmann Professor of Chemistry Professor of Chemistry at UMass Amherst. His research program focuses on using synthetic organic chemistry to engineer the interface between hard and soft materials and spans the areas of devices, polymers, and nanotechnology/bionanotechnology, with over 460 peer-reviewed papers published to date. He is actively involved in the development of new nanomanufacturing methods and in the area of bionanotechnology.
His research includes programs in delivery, imaging, diagnostics and nanotoxicology.
During his visit to Australia Professor Rotello visited labs and gave seminars:
Professor Leaf Huang is a biophysicist at the Eshelman School of Pharmacy at the University of North Carolina. Work in his Laboratory of Drug Targeting focuses on liposomes and immunoliposomes for drug delivery, with current research in siRNA therapy, and receptor mediated drug and vaccine targeting using self-assembled nanoparticles.
During his visit to Australia Professor Huang visited labs and gave seminars:
2014’s Visiting Professor, Mark E. Davis from Caltech, was co-hosted with the Australian Centre for Nanomedicine.
Professor Davis is actively involved in the creation, development and translation of nanoparticle delivery systems for gene silencing and drug delivery in humans. He is the senior author of a Nature paper describing the first example of RNA interference in humans as part of a first-in-human clinical trial of siRNA delivery via targeted nanoparticles for cancer (Nature 2010, 464, 1067).
During his visit to Australia Professor Davis visited labs and gave seminars: